SCHEMBL5658782

SCHEMBL5658782

Cc1cc(C2(c3ccc([N+](=O)[O-])cc3)C(=O)N(Cc3ccccc3Cl)c3ccccc32)cc(C)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HSD17B10 Q99714 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
CNR1 P21554 1/20 0.43
GPR55 Q9Y2T6 1/20 0.43
MAPT P10636 8/20 0.42
POLB P06746 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GFER P55789 1/20 0.40
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
MDM2 Q00987 3/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PLA2G1B P04054 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659726 0.89 TP53 (0.52) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5658322 0.89 MAPT (0.47) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5660174 0.89 CNR1 (0.57) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5659386 0.88 GFER (0.52) TP53ALDH1A1HSD17B10SMN1; SMN2LMNA
SCHEMBL5658562 0.87 CNR1 (0.47) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5658580 0.85 TP53 (0.48) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL14457600 0.83 MAPT (0.44) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5659557 0.83 TP53 (0.45) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5661002 0.81 TP53 (0.45) TP53ALDH1A1HSD17B10SMN1; SMN2HTT
SCHEMBL5661178 0.80 TP53 (0.49) TP53ALDH1A1HSD17B10SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 TP53 3370/4885ALDH1A1 723/4885HSD17B10 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.